Search Results - (Author, Cooperation:V. J. Suman)

Showing 1 - 2 results of 2, query time: 0.08s Refine Results
  1. 1
    M. J. Ellis ; L. Ding ; D. Shen ; J. Luo ; V. J. Suman ; J. W. Wallis ; B. A. Van Tine ; J. Hoog ; R. J. Goiffon ; T. C. Goldstein ; S. Ng ; L. Lin ; R. Crowder ; J. Snider ; K. Ballman ; J. Weber ; K. Chen ; D. C. Koboldt ; C. Kandoth ; W. S. Schierding ; J. F. McMichael ; C. A. Miller ; C. Lu ; C. C. Harris ; M. D. McLellan ; M. C. Wendl ; K. DeSchryver ; D. C. Allred ; L. Esserman ; G. Unzeitig ; J. Margenthaler ; G. V. Babiera ; P. K. Marcom ; J. M. Guenther ; M. Leitch ; K. Hunt ; J. Olson ; Y. Tao ; C. A. Maher ; L. L. Fulton ; R. S. Fulton ; M. Harrison ; B. Oberkfell ; F. Du ; R. Demeter ; T. L. Vickery ; A. Elhammali ; H. Piwnica-Worms ; S. McDonald ; M. Watson ; D. J. Dooling ; D. Ota ; L. W. Chang ; R. Bose ; T. J. Ley ; D. Piwnica-Worms ; J. M. Stuart ; R. K. Wilson ; E. R. Mardis
    Nature Publishing Group (NPG)
    Published 2012
    Staff View
    Publication Date:
    2012-06-23
    Publisher:
    Nature Publishing Group (NPG)
    Print ISSN:
    0028-0836
    Electronic ISSN:
    1476-4687
    Topics:
    Biology
    Chemistry and Pharmacology
    Medicine
    Natural Sciences in General
    Physics
    Keywords:
    Androstadienes/pharmacology/therapeutic use ; Antineoplastic Agents/pharmacology/therapeutic use ; Aromatase/*metabolism ; Aromatase Inhibitors/*therapeutic use ; Breast Neoplasms/*drug therapy/*genetics/metabolism/pathology ; DNA Repair ; Exome/genetics ; Exons/genetics ; Female ; Genetic Variation/genetics ; Genome, Human/*genetics ; Humans ; MAP Kinase Kinase 4/genetics ; MAP Kinase Kinase Kinase 1/genetics ; Mutation/genetics ; Nitriles/pharmacology/therapeutic use ; Receptors, Estrogen/metabolism ; Treatment Outcome ; Triazoles/pharmacology/therapeutic use
    Published by:
    http://www.nature.com/

    Latest Papers from Table of Contents or Articles in Press
  2. 2
    Rayson, D. ; Adjei, A. A. ; Suman, V. J. ; Wold, L. E. ; Ingle, J. N.
    Springer
    Published 1999
    Staff View
    ISSN:
    1569-8041
    Keywords:
    metaplastic breast cancer ; prognosis ; systemic therapy
    Source:
    Springer Online Journal Archives 1860-2000
    Topics:
    Medicine
    Notes:
    Abstract Background: Metaplastic breast cancer is a rare disease with little information available to guide therapy. The goals of this study were to describe the patient characteristics, systemic therapies and clinical outcomes of all patients with primary metaplastic breast cancer treated at Mayo Clinic between 1976 and 1997. Patients and methods: Patients were identified through the medical index of Mayo Clinic. Clinical information was abstracted from the medical record of each patient. A literature search using MEDLINE and CANCERLIT for the years 1966–1997 was performed to identify all previously reported case series in the English language containing 10 or more patients. Results: Twenty-seven patients were identified with a median age at diagnosis of 59 years (range 39–90 years). The median tumor size was 3.4 cm (range 0.5–7.0 cm). One patient had metastatic disease at presentation. Twenty-three patients had information available on nodal status, estrogen receptor (ER) and progesterone receptor (PR) status. Twenty patients (87%) were node-negative and three patients (13%) were both ER and PR positive. Disease-free survival (DFS) and overall survival (OS) were assessed for those who presented with local-regional disease. The three-year DFS was 40% (95% CI: 23%–73%) and the three-year OS was 71% (95% CI: 51%–97%). In univariate analysis, those patients 60 years of age or older at diagnosis were found to have an increased DFS (P = 0.011). Among those with prior estrogen use, both DFS (P = 0.022) and OS (P = 0.003) were decreased. Thirteen patients (50%) developed metastases with a median DFS time of 2.4 years. Ten different chemotherapy regimens were utilized for metastatic disease and one partial response was observed. There were no responses to tamoxifen in four patients with metastatic disease. Median survival after the development of metastases was eight months. Conclusions: Despite presenting more commonly as node-negative disease, DFS and OS in metaplastic breast cancer is decreased compared to typical adenocarcinomas. Systemic therapy also appears to be less effective. Patients with metaplastic breast cancer, particularly those with metastatic disease could be appropriate candidates for innovative therapeutic regimens.
    Type of Medium:
    Electronic Resource
    URL:
    http://dx.doi.org/10.1023/A:1008329910362

    Articles: DFG German National Licenses